#USA #Irvine #B. Braun #Heparin Sodium #injection products

B. Braun Expands Heparin Sodium Injection Portfolio

B. Braun Medical Inc., a recognized name in smart infusion therapy and pain management, has announced the launch of two new Heparin Sodium Injection products in the United States. This initiative expands their existing portfolio to a remarkable total of seven Heparin Premixed Sodium Injection products, establishing B. Braun as the leader in this market segment.

The newly introduced products include a 25,000 Units Heparin in 0.45% Sodium Chloride Injection at two different concentrations: 50 units/mL and 100 units/mL. These additions are significant for healthcare providers, as they offer enhanced options for patient care, especially in maintaining catheter patency through effective anticoagulation therapy.

Addressing Needs in Patient Care

The expanded portfolio comes at a time of increasing demand for precise and reliable healthcare solutions. B. Braun's commitment is reflected in their strategic move to deliver the largest selection of premixed Heparin products in the U.S. market. With careful attention, the new premixed bags will also incorporate an upgraded 2D enhanced barcode system, which includes critical information such as the National Drug Code (NDC), lot number, and expiration date. This design enhancement aims to facilitate more accurate and efficient barcode scanning, ultimately ensuring that healthcare workers have the tools they need to deliver precise and timely care to their patients.

Commitment to Safety and Quality

One pivotal aspect of B. Braun's offerings is their commitment to patient and environmental safety. The Heparin Sodium injections are manufactured using EXCEL® IV Containers, which are free from harmful substances like DEHP, PVC, and natural rubber latex. This initiative demonstrates B. Braun's dedication not just to patient health but also to sustainable health solutions that prioritize the environment. The production and distribution of these Heparin products take place at B. Braun's state-of-the-art pharmaceutical manufacturing facility located in Irvine, California.

Shawn Brinson, Director of Marketing for Injectable Drugs at B. Braun, expressed, "Expanding our Heparin Sodium Injection portfolio underscores our commitment to healthcare providers and their patients. By offering the largest selection of premixed Heparin products in the market, we are helping to provide healthcare workers with the tools they need to deliver precise and effective care."

Indications and Safety Information

The newly launched Heparin Sodium products are indicated as anticoagulants for maintaining catheter patency, which is crucial for numerous medical procedures. However, potential users should be aware of important safety information. These products are contraindicated for individuals with a history of heparin-induced thrombocytopenia (HIT), known hypersensitivity to heparin or pork products, or those who cannot undergo appropriate blood coagulation tests. Additionally, the products should not be used in patients experiencing uncontrollable active bleeding, except if associated with disseminated intravascular coagulation.

Incorporating these new offerings into healthcare settings allows providers greater flexibility and a broader range of options in anticoagulation therapy, ultimately leading to improved patient outcomes.

About B. Braun

B. Braun Medical Inc. is dedicated to innovating smart infusion therapy and developing safe, effective pharmacy products. The company’s drive is to enhance patient care and satisfaction, empowering healthcare professionals by simplifying their focus on patients. Based in Bethlehem, Pennsylvania, B. Braun employs around 8,500 people across more than 30 locations in North America, contributing to the company’s global workforce of over 64,000 employees worldwide. The organization operates under the philosophy of Sharing Expertise® to address the critical challenges in healthcare, continually exchanging knowledge with customers and partners to improve care delivery while managing costs.

For more detailed information, healthcare professionals can refer to the product’s full prescribing information, which outlines important safety considerations and usage guidelines.

In conclusion, the introduction of B. Braun's Heparin Sodium Injection products not only expands their portfolio but significantly contributes to enhanced patient care across the healthcare board, ensuring that healthcare providers have access to essential tools necessary for effective patient management.